Search
Search
London researchers get $2.8 million in funding to support mental health and wellbeing of Canadian health care workers
LONDON, ON - The COVID-19 pandemic has had a tangible impact on the mental health and wellbeing of Canadian health care workers, who have faced challenges that include increased workloads, resource constraints and fears of exposure to COVID-19.
Announced today, researchers out of Lawson Health Research Institute's MacDonald Franklin OSI Research Centre, have received $2.8 million in funding from the Public Health Agency of Canada (PHAC) to launch a project that will support the mental health and wellbeing of Canadian health care workers. The project is titled “Promoting Resilience and Mental Health: Adapting Canada’s Department of National Defence Road to Mental Readiness (R2MR) Program to Support Canadian Health Care Workers.”
The project will adapt the current Road to Mental Readiness Program, created for the Canadian Military. The aim is to identify mental health and wellness barriers in health care institutions, and create a streamlined framework that will build and promote supportive environments within institutions across the nation.
“This program has been a personalized approach with the military, and we are now adapting it to focus on Canadian health care workers,” explains Dr. Anthony Nazarov, Associate Scientist at Lawson and the MacDonald Franklin OSI Research Centre at St. Joseph’s Health Care London. “We want to educate institutions to create an environment that supports wellness not just at the individual level, but at the institutional level as well.”
The project, which will span 14 months, will assist in the planning, adaptation and testing of the health care focused Road to Mental Readiness Program.
“One of the main reasons we felt this was necessary stems from a recent study our team conducted that focused on moral distress and the mental health of Canadian health care workers,” says Dr. Don Richardson, Lawson Scientist and Director of the MacDonald Franklin OSI Research Centre at St. Joseph’s. “Our preliminary study results found that many Canadian health care workers have been negatively impacted by the pandemic with conditions such as; posttraumatic stress disorder, stress and depression.”
Once the research team has adapted the current Road to Mental Readiness Program, they will test it with health care workers to confirm its efficacy.
“We hope to have this type of resiliency program adopted by health care organizations across the country,” explains Dr. Richardson. “If proven effective, this would provide additional tools to health care workers to help them cope, improve their resiliency and hopefully mitigate future staff shortages.”
The funding is part of the federal 2021 budget which has committed an investment of $50 million over two years to support projects that address posttraumatic stress disorder and trauma in frontline and essential workers, and others affected by the pandemic. The nine projects announced, totaling an investment of $28.2 million, is the first round of projects being supported through this Budget 2021 commitment.
Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world. To learn more, visit www.lawsonresearch.ca.
Senior Media Relations Consultant
Communications & Public Engagement
T: 519-685-8500 ext. 73502
Celine.zadorsky@lhsc.on.ca
London researchers working on a proactive approach to inclusiveness in the classroom
LONDON, ON – Researchers at Lawson Health Research Institute have launched a pilot study and pilot project called Queer in the Classroom, to examine the benefits of a proactive, inclusive approach within the education system for those who are part of the 2SLBTGQIA+ student community.
“The Queer in the Classroom initiative is so important because when we look at the data, youth in the 2SLGBTQIA+ community are 14 times more likely to die by suicide,” says Dr. Arlene MacDougall, Lawson Scientist, Director of MINDS and Psychiatrist at St. Joseph’s Health Care London. “We need to be focusing on this population who are also experiencing a higher degree of isolation, stigma and substance use.”
The pilot project focuses on professional development for teachers and staff to help create an environment that is tailored to best support 2SLGBTQIA+ students through the additional stress they face as a minority group.
“This project is about connecting with school boards and teachers to help develop the knowledge and skills to create spaces that go beyond tolerating differences,” explains MacDougall. “The focus is to create an environment that is more affirming, that is more responsive and more proactive rather than reactive.”
The foundation for the pilot project came from a scoping review of existing research on this topic conducted by the research team through the Mental Health INcubator for Disruptive Solutions (MINDS), that looked extensively at how teachers themselves can create a classroom that embraces all students.
“We further conducted our own research based on a series of interviews of 2SLGBTQIA+ students at both elementary and secondary schools in Ontario, and their parents and teachers. We focused on not only their safety in school, but also being celebrated for who they are,” says Iylah Neves, Lawson Research Assistant through MINDS. “We drew on all of this research to best inform the practices we are using with the Queer in the Classroom initiative.”
Currently the Queer in the Classroom project is being rolled out on a ‘by-request’ basis. However, the research team is working with a couple of school boards within Ontario to discuss the possibility of wider implementation.
“Queer in the Classroom has been driven by the voices of students with personal experiences who feel there is a deep need for this type of innovation,” says Neves. “It is our responsibility to make those changes so that students can access a safe, inclusive and nurturing environment.”
Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world. To learn more, visit www.lawsonresearch.ca.
Senior Media Relations Consultant
Communications & Public Engagement
T: 519-685-8500 ext. 73502
Celine.zadorsky@lhsc.on.ca
London researchers working on a proactive approach to inclusiveness in the classroom
Researchers at Lawson Health Research Institute have launched a pilot study and pilot project called Queer in the Classroom, to examine the benefits of a proactive, inclusive approach within the education system for those who are part of the 2SLBTGQIA+ student community.
“The Queer in the Classroom initiative is so important because when we look at the data, youth in the 2SLGBTQIA+ community are 14 times more likely to die by suicide,” says Dr. Arlene MacDougall, Lawson Scientist, Director of MINDS and Psychiatrist at St. Joseph’s Health Care London. “We need to be focusing on this population who are also experiencing a higher degree of isolation, stigma and substance use.”
The pilot project focuses on professional development for teachers and staff to help create an environment that is tailored to best support 2SLGBTQIA+ students through the additional stress they face as a minority group.
“This project is about connecting with school boards and teachers to help develop the knowledge and skills to create spaces that go beyond tolerating differences,” explains MacDougall. “The focus is to create an environment that is more affirming, that is more responsive and more proactive rather than reactive.”
The foundation for the pilot project came from a scoping review of existing research on this topic conducted by the research team through the Mental Health INcubator for Disruptive Solutions (MINDS), that looked extensively at how teachers themselves can create a classroom that embraces all students.
“We further conducted our own research based on a series of interviews of 2SLGBTQIA+ students at both elementary and secondary schools in Ontario, and their parents and teachers. We focused on not only their safety in school, but also being celebrated for who they are,” says Iylah Neves, Lawson Research Assistant through MINDS. “We drew on all of this research to best inform the practices we are using with the Queer in the Classroom initiative.”
Currently the Queer in the Classroom project is being rolled out on a ‘by-request’ basis. However, the research team is working with a couple of school boards within Ontario to discuss the possibility of wider implementation.
“Queer in the Classroom has been driven by the voices of students with personal experiences who feel there is a deep need for this type of innovation,” says Neves. “It is our responsibility to make those changes so that students can access a safe, inclusive and nurturing environment.”
London scientists clinch $2 million in federal funding to develop better imaging tools for brain disease
LONDON, ON – Lawson Health Research Institute has been awarded over $2 million in federal funding for a project focusing on two unique medical imaging systems designed to give unparalleled insight into brain function and disease.
Today, the Right Honourable Justin Trudeau, Prime Minister of Canada, announced more than $518 million in research infrastructure support through the Canada Foundation for Innovation (CFI). In a live conversation today at 1 p.m., the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, will share more about how the funding will support 102 state-of-the-art projects at 35 post-secondary institutions and research hospitals across the country - helping Canada remain at the forefront of exploration, innovation and discovery.
“Imaging technologies, such as MRI and PET scanners, have revolutionized our understanding and treatment of major neurological diseases, including dementia and mental illness, by allowing us to study disease mechanisms and their impact on brain health,” says Dr. Keith St. Lawrence, Lawson Scientist and project co-lead. “We are developing and testing two leading-edge systems that will enable imaging of key vascular, metabolic and molecular factors linked to disease.”
The first system is a head-only PET (positron emission tomography) insert that can be placed in any clinical MRI machine. Combining the molecular specificity of PET with the structural and functional capabilities of MRI, the possibilities for brain imaging will be greatly enhanced. The head-only PET insert being tested in London has been developed by Cubresa Inc., located in Winnipeg, Manitoba.
“Combined with deep-learning approaches, we could achieve a highly improved sensitivity of the PET insert and reduce the radiation dose by up to 50 times compared to whole-body imaging,” explains Dr. Jonathan Thiessen, Lawson Scientist and project co-lead. “This will be the first commercially available high-resolution brain PET/MRI installed in the world.”
For example, better diagnosis of different forms of dementias would be possible and researchers could closely compare protein abnormalities in the brain with cognitive function. The low radiation dose allows for long-term studies investigating changes in the brain and neuroinflammation that can lead to major psychiatric diseases and cognitive degeneration or disability.
The second system uses portable, state-of-the-art optical imaging to increase the reliability of bedside brain monitoring to provide rapid assessment of brain health in restrictive environments.
“We believe this technology will demonstrate how biomedical optics can improve neurological outcome for surgery and patients in intensive care, provide an accessible technology for assessing neurovascular health, and become a clinically relevant tool for monitoring changes in brain function,” says Dr. St. Lawrence.
With current systems, the type of data is limited and extremely vulnerable to signal contamination from the scalp which can overshadow signals from the brain. Using the team’s specialized detection approach, the scalp signal contributions could be greatly reduced to get more accurate information on markers of brain activity, such as cerebral blood flow and energy metabolism.
The team will study use of the system in surgical and intensive-care settings to monitor for cerebral ischemia and metabolic stress, which are the major causes of brain injury. They will also monitor treatment in patients with schizophrenia and study dysfunction in the brain associated with negative symptoms, as cognitive impairment deteriorates with age for some people with the disease. Another goal is to develop a brain-computer interface for patients who are incapable of physical communication.
“With this funding, we can develop a truly unique advancement that has the potential to test the limits of optics for brain applications,” adds Dr. Thiessen. These two imaging platforms build on previous investments in Lawson Imaging that now exceed over $40 million in research funds since the initial CFI support in hybrid imaging in 2007.
-30-
Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world. To learn more, visit www.lawsonresearch.ca.
Senior Media Relations Consultant
Communications & Public Engagement
T: 519-685-8500 ext. 73502
Celine.zadorsky@lhsc.on.ca
London scientists clinch $2 million in federal funding to develop better imaging tools for brain disease
Lawson Health Research Institute has been awarded over $2 million in federal funding for a project focusing on two unique medical imaging systems designed to give unparalleled insight into brain function and disease.
The Right Honourable Justin Trudeau, Prime Minister of Canada, announced more than $518 million in research infrastructure support through the Canada Foundation for Innovation (CFI).
“Canada's researchers and scientists are some of the brightest and most skilled in the world. These investments will ensure that they have the cutting-edge laboratories and equipment needed to help us build a Canada that is healthier, greener, and more competitive," says The Rt. Hon. Justin Trudeau, Prime Minister of Canada.
In a live conversation, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, shared more about how the funding will support 102 state-of-the-art projects at 35 post-secondary institutions and research hospitals across the country - helping Canada remain at the forefront of exploration, innovation and discovery.
The first system is a head-only PET (positron emission tomography) insert that can be placed in any clinical MRI machine. Combining the molecular specificity of PET with the structural and functional capabilities of MRI, the possibilities for brain imaging will be greatly enhanced. The head-only PET insert being tested in London has been developed by Cubresa Inc., located in Winnipeg, Manitoba.
For example, better diagnosis of different forms of dementias would be possible and researchers could closely compare protein abnormalities in the brain with cognitive function. The low radiation dose allows for long-term studies investigating changes in the brain and neuroinflammation that can lead to major psychiatric diseases and cognitive degeneration or disability.
The second system uses portable, state-of-the-art optical imaging to increase the reliability of bedside brain monitoring to provide rapid assessment of brain health in restrictive environments.
“We believe this technology will demonstrate how biomedical optics can improve neurological outcome for surgery and patients in intensive care, provide an accessible technology for assessing neurovascular health, and become a clinically relevant tool for monitoring changes in brain function,” says Dr. St. Lawrence.
With current systems, the type of data is limited and extremely vulnerable to signal contamination from the scalp which can overshadow signals from the brain. Using the team’s specialized detection approach, the scalp signal contributions could be greatly reduced to get more accurate information on markers of brain activity, such as cerebral blood flow and energy metabolism.
The team will study use of the system in surgical and intensive-care settings to monitor for cerebral ischemia and metabolic stress, which are the major causes of brain injury. They will also monitor treatment in patients with schizophrenia and study dysfunction in the brain associated with negative symptoms, as cognitive impairment deteriorates with age for some people with the disease. Another goal is to develop a brain-computer interface for patients who are incapable of physical communication.
“With this funding, we can develop a truly unique advancement that has the potential to test the limits of optics for brain applications,” adds Dr. Thiessen.
These two imaging platforms build on previous investments in Lawson Imaging that now exceed over $40 million in research funds since the initial CFI support in hybrid imaging in 2007. London is home to Canada’s first whole body PET/MRI scanner that was installed at St. Joseph’s Hospital, part of St. Joseph’s Health Care London.
Machine learning could predict medication response in patients with complex mood disorders
Mood disorders like major depressive disorder (MDD) and bipolar disorder are often complex and hard to diagnose, especially among youth when the illness is just evolving. This can make decisions about medication difficult. In a collaborative study by Lawson Health Research Institute, The Mind Research Network and Brainnetome Center, researchers have developed an artificial intelligence (AI) algorithm that analyzes brain scans to better classify illness in patients with a complex mood disorder and help predict their response to medication.
The full study included 78 emerging adult patients from mental health programs at London Health Sciences Centre (LHSC), primarily from the First Episode Mood and Anxiety Program (FEMAP). The first part of the study involved 66 patients who had already completed treatment for a clear diagnosis of either MDD or bipolar type I (bipolar I), which is a form of bipolar disorder that features full manic episodes, as well as an additional 33 research participants with no history of mental illness. Each individual participated in scanning to examine different brain networks using Lawson’s functional magnetic resonance imaging (fMRI) capabilities at St. Joseph’s Health Care London.
The research team analyzed and compared the scans of those with MDD, bipolar I and no history of mental illness, and found the three groups differed in particular brain networks. These included regions in the default mode network, a set of regions thought to be important for self-reflection, as well as in the thalamus, a ‘gateway’ that connects multiple cortical regions and helps control arousal and alertness.
The data was used by researchers at The Mind Research Network to develop an AI algorithm that uses machine learning to examine fMRI scans to classify whether a patient has MDD or bipolar I. When tested against the research participants with a known diagnosis, the algorithm correctly classified their illness with 92.4 per cent accuracy.
The research team then performed imaging with 12 additional participants with complex mood disorders for whom a diagnosis was not clear. They used the algorithm to study a participant’s brain function to predict his or her diagnosis and, more importantly, examined the participant’s response to medication.
“Antidepressants are the gold standard pharmaceutical therapy for MDD while mood stabilizers are the gold standard for bipolar I,” says Dr. Elizabeth Osuch, a clinician-scientist at Lawson, medical director at FEMAP and co-lead investigator on the study. “But it becomes difficult to predict which medication will work in patients with complex mood disorders when a diagnosis is not clear. Will they respond better to an antidepressant or to a mood stabilizer?”
The research team hypothesized that participants classified by the algorithm as having MDD would respond to antidepressants while those classified as having bipolar I would respond to mood stabilizers. When tested with the complex patients, 11 out of 12 responded to the medication predicted by the algorithm.
“Machine learning is an approach that learns in a data-centric way, providing information that can be used to predict future data sets. In this case, that’s the prediction of MDD from bipolar I,” says Dr. Vince Calhoun, President of The Mind Research Network; Distinguished Professor, Departments of Electrical and Computer Engineering, Neurosciences, Computer Science, and Psychiatry at The University of New Mexico; and co-lead investigator on the study. “There are multiple layers of algorithms in this project. The first layer includes an approach that automatically extracts brain networks from the data provided and the second layer includes automatically identifying which combinations of networks are most sensitive or predictive of MDD and bipolar I.”
Above: Dr. Vince Calhoun
“This study takes a major step towards finding a biomarker of medication response in emerging adults with complex mood disorders,” says Dr. Osuch. “It also suggests that we may one day have an objective measure of psychiatric illness through brain imaging that would make diagnosis faster, more effective and more consistent across health care providers.”
Psychiatrists currently make a diagnosis based on the history and behavior of a patient. Medication decisions are based on that diagnosis. “This can be difficult with complex mood disorders and in the early course of an illness when symptoms may be less well-defined,” says Dr. Osuch. “Patients may also have more than one diagnosis, such as a combination of a mood disorder and a substance abuse disorder, further complicating diagnosis. Having a biological test or procedure to identify what class of medication a patient will respond to would significantly advance the field of psychiatry.”
The study, “Complexity in mood disorder diagnosis: fMRI connectivity networks predicted medication-class of response in complex patients,” is published online in Acta Psychiatrica Scandinavica. Local support included donor funding through London Health Sciences Foundation.
Learn more about this research:
Above: Drs. Elizabeth Osuch and Jean Théberge, Lawson scientists